To include your compound in the COVID-19 Resource Center, submit it here.

PTAB denies Concert's challenge to Jakafi patent

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) said the U.S. Patent Trial and Appeal Board declined the company’s post grant review (PGR) petition challenging U.S. Patent No.

Read the full 244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE